866-997-4948(US-Canada Toll Free)

Aspergillosis - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 101 Pages

Aspergillosis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Pipeline Review, H1 2017, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 5, 19 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aspergillosis - Overview
Aspergillosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Aspergillosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aspergillosis - Companies Involved in Therapeutics Development
Amplyx Pharmaceuticals Inc
Astellas Pharma Inc
Biomar Microbial Technologies
Biosergen AS
Cidara Therapeutics Inc
F2G Ltd
Hsiri Therapeutics LLC
iCo Therapeutics Inc.
Matinas BioPharma Holdings Inc
Merck & Co Inc
Nanomerics Ltd
Novabiotics Ltd
Pulmatrix Inc
Pulmocide Ltd
Scynexis Inc
Sealife PHARMA GMBH
Sigma-Tau SpA
Vical Inc
Visterra Inc
Aspergillosis - Drug Profiles
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-001A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-9726 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspergillus fumigatus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BSG-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
celastrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-901318 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-425796C - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDN-0018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-339 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PC-945 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
posaconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTX-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCY-078 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Aspergillosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Aspergillosis and Candidiasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Invasive Aspergillosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-FNG - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VL-2397 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspergillosis - Dormant Projects
Aspergillosis - Discontinued Products
Aspergillosis - Product Development Milestones
Featured News & Press Releases
May 02, 2017: Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
Apr 25, 2017: Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
Apr 17, 2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID Annual Meetings
Jan 09, 2017: F2G Receives European Orphan Drug Designation for its Lead Candidate F901318
Dec 13, 2016: SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections
Nov 28, 2016: Cidara Therapeutics Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
Nov 16, 2016: FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
Oct 26, 2016: F2G Announces Publication of Initial F901318 Data in Scientific Journal PNAS
Sep 12, 2016: Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections
Aug 24, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH
Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections
May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors
Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis
Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Aspergillosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Aspergillosis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2017
Aspergillosis - Pipeline by Astellas Pharma Inc, H1 2017
Aspergillosis - Pipeline by Biomar Microbial Technologies, H1 2017
Aspergillosis - Pipeline by Biosergen AS, H1 2017
Aspergillosis - Pipeline by Cidara Therapeutics Inc, H1 2017
Aspergillosis - Pipeline by F2G Ltd, H1 2017
Aspergillosis - Pipeline by Hsiri Therapeutics LLC, H1 2017
Aspergillosis - Pipeline by iCo Therapeutics Inc., H1 2017
Aspergillosis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
Aspergillosis - Pipeline by Merck & Co Inc, H1 2017
Aspergillosis - Pipeline by Nanomerics Ltd, H1 2017
Aspergillosis - Pipeline by Novabiotics Ltd, H1 2017
Aspergillosis - Pipeline by Pulmatrix Inc, H1 2017
Aspergillosis - Pipeline by Pulmocide Ltd, H1 2017
Aspergillosis - Pipeline by Scynexis Inc, H1 2017
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H1 2017
Aspergillosis - Pipeline by Sigma-Tau SpA, H1 2017
Aspergillosis - Pipeline by Vical Inc, H1 2017
Aspergillosis - Pipeline by Visterra Inc, H1 2017
Aspergillosis - Dormant Projects, H1 2017
Aspergillosis - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Aspergillosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *